Fate Therapeutics Inc (NASDAQ:FATE) was up 8% during trading on Friday . The stock traded as high as $8.90 and last traded at $8.76. Approximately 935,510 shares were traded during trading, an increase of 52% from the average daily volume of 614,979 shares. The stock had previously closed at $8.11.
Several equities research analysts recently commented on FATE shares. BMO Capital Markets reiterated a “buy” rating and set a $7.00 target price on shares of Fate Therapeutics in a report on Thursday, November 2nd. HC Wainwright reiterated a “buy” rating on shares of Fate Therapeutics in a report on Thursday, November 2nd. ValuEngine downgraded Fate Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Raymond James Financial reiterated a “buy” rating on shares of Fate Therapeutics in a report on Tuesday, December 12th. Finally, Piper Jaffray Companies started coverage on Fate Therapeutics in a report on Monday, December 18th. They set an “overweight” rating and a $10.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Fate Therapeutics has an average rating of “Buy” and a consensus target price of $7.71.
The company has a debt-to-equity ratio of 0.32, a quick ratio of 7.21 and a current ratio of 7.21.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company grew its stake in Fate Therapeutics by 61.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 33,337 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 12,686 shares in the last quarter. Raymond James & Associates acquired a new stake in Fate Therapeutics during the 4th quarter valued at approximately $141,000. Hochman Cole Investment Advisors Inc. acquired a new stake in Fate Therapeutics during the 3rd quarter valued at approximately $158,000. New York State Common Retirement Fund acquired a new stake in Fate Therapeutics during the 2nd quarter valued at approximately $131,000. Finally, BlackRock Inc. grew its stake in Fate Therapeutics by 2.6% during the 4th quarter. BlackRock Inc. now owns 1,705,293 shares of the biopharmaceutical company’s stock valued at $10,421,000 after purchasing an additional 43,499 shares in the last quarter. Hedge funds and other institutional investors own 50.00% of the company’s stock.
WARNING: This piece of content was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://ledgergazette.com/2018/02/18/fate-therapeutics-fate-trading-up-8.html.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.